VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ULBI
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ULBIUltralife Corporation
$5.98$100M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksULBIFinancials

Ultralife Corporation (ULBI) Financials

30Y historyFree accessUpdated daily

Revenue growth has exhibited significant volatility, oscillating from a 31.4% expansion in 2024Q1 to a 6.5% contraction in 2026Q1, while gross margins have simultaneously compressed from 27.4% to 20.7% over the same period.

ULBI Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Jun'02Jun'01Jun'00Jun'99Jun'98Jun'97Jun'96
Sales/Revenue187.86M191.16M164.46M158.64M131.84M98.27M107.71M106.8M87.19M85.53M82.46M76.43M66.49M78.83M101.66M139.39M178.58M172.11M254.7M137.6M93.55M70.5M98.18M79.45M32.52M24.16M24.51M21.1M16.4M15.9M15.1M
Revenue Growth %8.42%16.24%3.66%20.33%34.17%-8.77%0.86%22.49%1.94%3.72%7.89%14.94%-15.65%-22.45%-27.07%-21.95%3.76%-32.43%85.11%47.09%32.69%-28.19%23.58%144.35%34.57%-1.43%16.18%28.66%3.14%5.3%3.42%
Cost of Goods Sold145.85M146.66M122.14M119.44M102.44M73.63M78.55M75.63M61.61M59.3M57.35M53.11M47.14M56.21M72.93M103.99M132.01M135.25M197.76M108.82M76.1M58.24M77.88M62.35M31.17M27.7M23.47M16.8M13.1M13.8M12.5M
COGS % of Revenue-76.72%74.27%75.29%77.7%74.92%72.93%70.82%70.66%69.33%69.55%69.49%70.9%71.31%71.74%74.61%73.92%78.58%77.64%79.09%81.35%82.61%79.32%78.48%95.86%114.62%95.76%79.62%79.88%86.79%82.78%
Gross Profit42.01M44.5M42.31M39.2M29.4M24.64M29.16M31.16M25.58M26.23M25.11M23.32M19.35M22.62M28.73M35.39M46.57M36.86M56.94M28.77M17.44M12.26M20.3M17.1M1.35M-3.53M1.04M4.3M3.3M2.1M2.6M
Gross Margin %22.36%23.28%25.73%24.71%22.3%25.08%27.07%29.18%29.34%30.67%30.45%30.51%29.1%28.69%28.26%25.39%26.08%21.42%22.36%20.91%18.65%17.39%20.68%21.52%4.14%-14.62%4.24%20.38%20.12%13.21%17.22%
Gross Profit Growth %-5.17%7.94%33.33%19.31%-15.49%-6.44%21.82%-2.47%4.48%7.69%20.5%-14.46%-21.26%-18.83%-24%26.34%-35.27%97.9%64.96%42.3%-39.62%18.75%1169.19%138.13%-439.71%-75.81%30.3%57.14%-19.23%8.33%
Operating Expenses38.15M35.28M32.35M29.73M29.27M24.61M23.46M23.8M19.03M19.76M21.34M19.84M20.79M23.25M28.84M32.92M38.66M44.22M39.64M28.97M20.4M15.16M15.21M11.12M26.56M11.43M14.73M14.3M13.9M9.9M9.5M
OpEx % of Revenue-18.46%19.67%18.74%22.2%25.04%21.78%22.28%21.82%23.1%25.89%25.95%31.27%29.49%28.37%23.62%21.65%25.69%15.56%21.06%21.81%21.5%15.49%13.99%81.68%47.32%60.08%67.77%84.76%62.26%62.91%
Selling, General & Admin28.22M26.28M24.08M22.19M22.19M17.78M17.51M16.99M14.52M15.02M15.4M14.23M15.46M17.39M21.63M24.32M29.84M34.68M31.5M21.97M15.3M11.41M10.77M8.61M7.95M8.01M7.38M6.2M5.8M5.2M8.7M
SG&A % of Revenue-13.75%14.64%13.99%16.83%18.09%16.26%15.91%16.65%17.56%18.67%18.62%23.25%22.05%21.28%17.45%16.71%20.15%12.37%15.97%16.36%16.18%10.97%10.84%24.45%33.15%30.13%29.38%35.37%32.7%57.62%
Research & Development9.93M9M8.27M7.53M7.08M6.83M5.95M6.8M4.51M4.74M5.95M5.6M5.33M5.86M7.22M8.6M8.82M9.54M8.14M7M5.1M3.75M2.63M2.5M4.29M3.42M5.31M5.9M6.7M3.9M0
R&D % of Revenue-4.71%5.03%4.75%5.37%6.95%5.52%6.37%5.17%5.54%7.21%7.33%8.02%7.43%7.1%6.17%4.94%5.54%3.2%5.09%5.45%5.32%2.68%3.15%13.2%14.17%21.64%27.96%40.85%24.53%-
Other Operating Expenses0000000058K-181K-183K65K-154K-26K-24K00000001.8M014.32M02.04M2.2M1.4M800K800K
Operating Income3.85M9.22M9.96M9.47M129K35K5.7M7.37M6.55M6.48M3.76M3.33M-1.44M-624K-114K2.48M-5.88M-7.36M17.3M-199K-2.96M-2.9M5.09M5.98M-25.21M-14.97M-13.69M-10M-10.6M-7.8M-6.9M
Operating Margin %2.05%4.82%6.06%5.97%0.1%0.04%5.29%6.9%7.52%7.57%4.56%4.36%-2.17%-0.79%-0.11%1.78%-3.29%-4.28%6.79%-0.14%-3.16%-4.12%5.19%7.53%-77.54%-61.94%-55.84%-47.39%-64.63%-49.06%-45.7%
Operating Income Growth %--7.48%5.17%7244.96%268.57%-99.39%-22.62%12.4%1.22%72.1%13%330.77%-131.25%-447.37%-104.61%142.08%20.12%-142.54%8795.98%93.27%-1.9%-156.96%-14.81%123.72%-68.46%-9.33%-36.89%5.66%-35.9%-13.04%-32.69%
EBITDA9.32M14.72M14.12M13.39M4.59M3.57M8.64M10.11M8.92M8.9M6.49M3.56M-1.14M-222K383K6.79M-531K-1.64M23.27M5.98M1.91M279K8.4M9.11M-20.95M-11.15M-11.65M-7.8M-9.2M-7M-6.1M
EBITDA Margin %4.96%7.7%8.59%8.44%3.48%3.64%8.02%9.47%10.24%10.41%7.87%4.66%-1.71%-0.28%0.38%4.87%-0.3%-0.95%9.14%4.35%2.04%0.4%8.56%11.47%-64.42%-46.17%-47.53%-36.97%-56.1%-44.03%-40.4%
EBITDA Growth %-32.7%4.23%5.5%191.76%28.37%-58.62%-14.61%13.32%0.24%37.2%82.02%413.27%-412.61%-157.96%-94.36%1379.47%67.52%-107.02%289.28%213.2%584.23%-96.68%-7.79%143.51%-87.77%4.26%-49.37%15.22%-31.43%-14.75%-32.61%
D&A (Non-Cash Add-back)5.46M5.5M4.16M3.91M4.46M3.54M2.94M2.75M2.37M2.43M2.73M235K305K402K497K4.32M5.35M5.73M5.97M6.18M4.87M3.18M3.31M3.13M4.26M3.81M2.04M2.2M1.4M800K800K
EBIT3.85M9.22M10.24M11.13M505K91K7.46M7.31M6.55M6.48M4.06M3.48M-1.58M-611K-134K2.65M12.01M-7.35M18.47M7.89M-2.96M-2.9M5.09M5.98M-39.24M-25.21M-14.97M-13.69M-10M-10.6M-7.8M
Net Interest Income-3.79M-3.95M-1.94M-2.02M-951K-242K-436K-539K-63K-183K-263K-245K-205K-199K-436K-554K-1.14M-1.47M-930K0-168K-1.09M-8.94M00000000
Interest Income000000000003K13K39K4K5K2K27K37K0126K185K116K00000000
Interest Expense3.79M3.95M1.94M2.02M951K242K436K539K63K183K263K248K218K238K440K559K1.17M1.49M967K0294K1.27M9.05M0-29K2.3M003.5M00
Other Income/Expense-15.36M-17.62M-1.66M-358K-575K-186K1.32M-597K58K-181K-183K-180K-359K-225K-460K-383K-18.74M-1.48M237K5.86M-796K-954K-3.87M572K29K7.95M-2.3M5.29M2.9M3.5M4.4M
Pretax Income-11.51M-8.4M8.3M9.12M-446K-151K7.02M6.77M6.61M6.29M3.58M3.15M-1.8M-849K-574K2.09M-6.88M-8.84M17.54M5.66M-3.75M-3.86M1.23M6.55M-25.18M-17.26M-11.15M-8.4M-7.1M-7.1M-3.4M
Pretax Margin %-6.13%-4.39%5.05%5.75%-0.34%-0.15%6.52%6.34%7.58%7.36%4.34%4.12%-2.71%-1.08%-0.56%1.5%-3.85%-5.14%6.89%4.11%-4.01%-5.47%1.25%8.25%-77.45%-71.44%-45.49%-39.81%-43.29%-44.65%-22.52%
Income Tax-3.21M-2.45M1.89M1.95M-326K79K1.69M1.46M-18.39M-1.37M98K310K268K239K554K528K-670K391K3.88M77K23.73M489K-21.1M106K04.76M-5.99M-4.5M-7.1M-1.3M-7.2M
Effective Tax Rate %27.86%29.14%22.79%21.4%73.09%-52.32%24.09%21.52%-278.03%-21.75%2.74%9.84%-14.87%-28.15%-96.52%25.24%9.74%-4.42%22.11%1.36%-632.43%-12.68%-1718.57%1.62%0%-27.56%53.67%53.57%100%18.31%211.76%
Net Income-8.21M-5.9M6.31M7.2M-119K-234K5.23M5.21M24.93M7.65M3.51M2.87M-2.12M-926K-1.6M-2.08M-6.18M-9.24M13.66M5.58M-27.49M-4.34M22.33M6.45M-25.18M-17.26M-10.24M-7.1M-7M-7.2M-3.2M
Net Margin %-4.37%-3.09%3.84%4.54%-0.09%-0.24%4.86%4.87%28.59%8.94%4.26%3.75%-3.18%-1.17%-1.57%-1.49%-3.46%-5.37%5.36%4.06%-29.38%-6.16%22.75%8.11%-77.45%-71.44%-41.78%-33.65%-42.68%-45.28%-21.19%
Net Income Growth %-255.39%-193.44%-12.3%6147.9%49.15%-104.47%0.52%-79.12%225.97%117.95%22.31%235.59%-128.51%42.05%23.17%66.34%33.13%-167.64%144.73%120.31%-532.64%-119.46%246.39%125.6%-45.88%-68.54%-44.25%-1.43%2.78%-125%5.88%
Net Income (Continuing)-8.3M-5.95M6.41M7.17M-120K-230K5.33M5.31M25M7.66M3.48M2.84M-2.07M-1.09M-1.13M1.55M-6.21M-9.23M13.63M5.58M-27.49M-4.34M22.33M6.45M-25.18M-25.18M-17.26M-10.24M-7.1M-7M-7.2M
Discontinued Operations0000000000000128K00000000000000000
Minority Interest119K139K192K95K126K127K123K24K-85K-154K-170K-143K-114K-99K-65K-34K24K54K21K000000000000
EPS (Diluted)-0.49-0.350.380.44-0.01-0.010.330.321.530.480.230.17-0.12-0.05-0.09-0.12-0.36-0.540.780.36-1.84-0.301.480.46-2.03-1.55-0.94-0.68-0.84-0.91-0.41
EPS Growth %-257.02%-192.11%-13.64%-49.32%-104.42%3.13%-79.09%218.75%108.7%35.29%241.67%-126.42%42.27%23.5%66.67%33.33%-169.23%116.67%119.57%-513.33%-120.27%221.74%122.66%-30.97%-64.89%-38.24%19.05%7.69%-121.95%18%
EPS (Basic)--0.350.380.44-0.01-0.010.330.331.570.490.230.18-0.12-0.05-0.09-0.12-0.36-0.540.790.36-1.84-0.301.590.49-2.03-1.55-0.94-0.68-0.84-0.91-0.41
Diluted Shares Outstanding16.66M16.64M16.77M16.23M16.13M16.04M16.1M16.18M16.35M15.86M15.4M16.42M17.48M17.46M17.4M17.34M17.16M16.99M17.68M15.56M14.91M14.55M15.07M13.92M12.41M11.14M10.9M10.48M8.34M7.92M7.8M
Basic Shares Outstanding16.66M16.64M16.55M16.36M16.13M16.04M15.9M15.78M15.88M15.53M15.26M16.18M17.13M17.46M17.4M17.3M17.16M16.99M17.23M15.32M14.91M14.55M14.09M13.13M12.41M11.14M10.9M10.48M8.34M7.92M7.8M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetHealthy
Cash FlowDeteriorating
Top Statement Risk

Margin volatility and scale

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Lacks Consistent Momentum

According to the provided quarterly income statements, Ultralife's revenue growth has exhibited significant volatility, oscillating between a 31.4% expansion in 2024Q1 and a 6.5% contraction by 2026Q1, suggesting that the company's top-line performance remains highly sensitive to the timing of specific defense and industrial project deliveries.

The inconsistent revenue trajectory indicates that Ultralife struggles to maintain a steady pipeline of project-based work, likely due to the lumpy nature of government contract milestones. Investors should monitor whether the recent contraction reflects a structural slowdown in demand or merely the timing of revenue recognition across its two primary business segments.

Structural Margin Compression Remains Persistent

As reported in financial statements, Ultralife's gross margin has trended downward from a peak of 27.4% in 2024Q1 to 20.7% in 2026Q1, indicating that the company is facing mounting pressure from input costs that it has been unable to fully pass on to its defense and industrial customers.

This margin erosion suggests a lack of pricing power in its core battery and energy products, potentially exacerbated by inflationary pressures on raw materials like lithium. The inability to sustain gross margins above 25% raises concerns regarding the company's competitive positioning and the long-term viability of its current product mix.

Operating Leverage Fails to Materialize

Based on the company's reported figures, operating income has deteriorated from a positive $4.1 million in 2024Q1 to a loss of $215,000 in 2026Q1, demonstrating that the company has failed to achieve the necessary operating leverage to scale its profitability alongside its revenue fluctuations.

The lack of operating leverage implies that fixed costs, including R&D and SG&A, are consuming an increasing share of gross profit, leaving little room for bottom-line growth. This trend warrants further investigation into whether management can effectively rationalize its cost structure or if the current operating model is inherently inefficient at this scale.

Profitability Challenges Mask Operational Risks

Analysis of the income statement reveals that Ultralife has slipped into a net loss position, with net margins falling to -3.09% in the most recent period, which suggests that the company's current business model may be structurally incapable of generating consistent shareholder value under existing cost conditions.

Short-sellers would likely focus on the persistent inability to convert revenue growth into net income, viewing the recent losses as a sign of deeper operational dysfunction. The transition from consistent profitability in early 2024 to recent quarterly losses suggests that the company's niche market focus may not provide the protection from cyclicality that investors previously anticipated.

ULBI — Frequently Asked Questions

Quick answers to the most common questions about buying ULBI stock.

What was Ultralife Corporation's (ULBI) revenue in 2025?

For fiscal year 2025, Ultralife Corporation (ULBI) reported total revenue of $191.2M. This represents a 1166.0% increase compared to $15.1M in 1996.

Is Ultralife Corporation (ULBI) profitable?

Ultralife Corporation (ULBI) reported a net loss of $5.9M for the fiscal year ending 2025.

What is Ultralife Corporation's operating profit margin?

Ultralife Corporation (ULBI) reported an operating income of $9.2M, resulting in an operating profit margin of 4.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Ultralife Corporation's gross profit and gross margin?

Ultralife Corporation (ULBI) generated $44.5M in gross profit for the year, representing a gross profit margin of 23.3%. This demonstrates the company's core pricing power and production efficiency.